Hims & Hers Health, Inc. (BMV:HIMS)
Mexico · Delayed Price · Currency is MXN | Market Cap | 112.42B -8.2% |
| Revenue (ttm) | 42.26B +59.0% |
| Net Income | 2.31B +1.8% |
| EPS | 9.22 -3.7% |
| Shares Out | n/a |
| PE Ratio | 48.65 |
| Forward PE | 24.58 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,445 |
| Average Volume | 6,196 |
| Open | 438.00 |
| Previous Close | 443.63 |
| Day's Range | 437.70 - 484.50 |
| 52-Week Range | 240.00 - 1,330.00 |
| Beta | 2.42 |
| RSI | 55.90 |
| Earnings Date | May 11, 2026 |
About Hims & Hers Health
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and de... [Read more]
Financial Performance
In 2025, Hims & Hers Health's revenue was $2.35 billion, an increase of 59.00% compared to the previous year's $1.48 billion. Earnings were $128.37 million, an increase of 1.85%.
Financial numbers in USD Financial StatementsNews
Polymarket Earnings: Will HIMS, CRCL, QUBT Beat Earnings on Monday?
On Monday, May 11, Hims & Hers Health ($HIMS), Circle ($CRCL), and Quantum Computing ($QUBT) will report their earnings. Circle will report before the market open, while Hims & Hers and
HIMS Stock Options Traders Are Pricing In a Huge Price Swing after Earnings
Hims & Hers Health ($HIMS) stock options traders are pricing in a sharp move ahead of the healthcare company’s earnings. With the stock trading around $26.25, we will use the
Hims & Hers (HIMS) Set to Report Q1 Earnings — Here’s What Analysts Expect
Hims & Hers Health ($HIMS) will report its Q1 2026 earnings on May 11. The telehealth company heads into earnings with strong recent momentum, with HIMS stock gaining more than
Mixed options sentiment in Hims and Hers Health with shares down 3.44%
Mixed options sentiment in Hims and Hers Health (HIMS), with shares down 92c near $25.95. Options volume relatively light with 35k contracts traded and calls leading puts for a put/call
Moderately bullish activity in Hims and Hers Health with shares down 1.2%
Moderately bullish activity in Hims and Hers Health (HIMS), with shares down 33c near $27.08. Options volume relatively light with 70k contracts traded and calls leading puts for a put/call
Mixed options sentiment in Hims and Hers Health with shares down 4.95%
Mixed options sentiment in Hims and Hers Health (HIMS), with shares down $1.46 near $27.93. Options volume relatively light with 147k contracts traded and calls leading puts for a put/call
Hims & Hers Nominates Kofi Amoo-Gottfried to its Board of Directors
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, has nominated Kofi Amoo-Gottfried for election as a new director at the ...
Bullish flow in Hims and Hers Health with shares up 9.2%
Bullish flow in Hims and Hers Health (HIMS), with shares up $2.59, or 9.2%, near $30.74. Options volume running well above average with 243k contracts traded and calls leading puts
Now Is the Time to Buy Hims & Hers Stock (HIMS), Says JPMorgan Chase
Weight-loss drugs could be a big revenue generator.
Hims & Hers price target raised to $32 from $30 at BofA
BofA raised the firm’s price target on Hims & Hers (HIMS) to $32 from $30 and keeps a Neutral rating on the shares after the company announced that its platform
Hims & Hers likely to be up on LillyDirect announcement, says Leerink
Hims & Hers (HIMS) announced access to Eli Lilly (LLY) GLP-1 products through its platform, expanding its weight-loss offering, though its exact role and profit share in the arrangement remains
Hims & Hers (HIMS) Gets Good News from the FDA. Is It Already Priced in?
Hims & Hers Health, Inc. ($HIMS) just caught a regulatory break from the U.S. Food and Drug Administration (FDA), but I believe the good news is already largely priced in.
Hims & Hers expands into menopause care as estrogen patch demand rises
Telehealth company Hims & Hers said on Wednesday it will now offer treatment options for perimenopause and menopause via its platform, as rising U.S. demand for hormone therapy strains supplies of e...
Hims & Hers price target raised to $30 from $25 at BofA
BofA raised the firm’s price target on Hims & Hers (HIMS) to $30 from $25 and keeps a Neutral rating on the shares. Amazon’s (AMZN) new offering in the GLP-1
Mixed options sentiment in Hims and Hers Health with shares down 4.05%
Mixed options sentiment in Hims and Hers Health (HIMS), with shares down $1.25 near $29.75. Options volume running well above average with 310k contracts traded and calls leading puts for
RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves
Investors are starting to focus on what will replace compounded GLP-1 driven growth for telehealth companies like Hims & Hers Health. Peptides are gaining attention as a potential new growth vector, d...
Hims rises as FDA considers broader peptides access; analysts see long-term win
Shares of Hims & Hers Health rose more than 7% on Thursday as analysts said the U.S. drug regulator's consideration to allow compounding pharmacies to manufacture popular peptides could benefit the t...
Hims & Hers surges 4% as peptide policy shift unlocks growth
Shares of Hims & Hers Health moved sharply higher on Thursday, extending gains from the previous session after a significant regulatory shift signaled new opportunities in the peptide market. The stoc...
Hims & Hers Health Stock Rallies on Regulatory Pivot. It's Not About GLP-1s This Time.
Hims has signaled its interest in peptides, many of which have been banned for use in compounding pharmacies.
Hims & Hers stock jumps as U.S. moves forward with plan to reassess popular peptides
Hims & Hers Health's plan to enter the business of selling peptides is looking a lot more realistic.
Hims & Hers to Announce First Quarter 2026 Financial Results on May 11, 2026
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report first quarter 2026 financial results...
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES, April 08, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Hims & Hers Heal...
Hims & Hers Health Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Hims & Hers Health, Inc. - HIMS
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced...
Telehealth giant Hims & Hers says its customer support system was hacked
Hims & Hers, the telehealth company that sells weight-loss drugs and sexual health prescriptions, has confirmed a data breach affecting its third-party customer service platform.